TY - JOUR
T1 - Early-Onset Parkinson Disease Screening in Patients From Nigeria
AU - Milanowski, Lukasz M.
AU - Oshinaike, Olajumoke
AU - Broadway, Benjamin J.
AU - Lindemann, Jennifer A.
AU - Soto-Beasley, Alexandra I.
AU - Walton, Ronald L.
AU - Hanna Al-Shaikh, Rana
AU - Strongosky, Audrey J.
AU - Fiesel, Fabienne C.
AU - Ross, Owen A.
AU - Springer, Wolfdieter
AU - Ogun, Shamsideen Abayomi
AU - Wszolek, Zbigniew K.
N1 - Funding Information:
Funding. Mayo Clinic is an American Parkinson Disease Association (APDA) Mayo Clinic Information and Referral Center, an APDA Center for Advanced Research and the Mayo Clinic Lewy Body Dementia Association (LBDA) Research Center of Excellence. LM is supported by the Polish National Agency for Academic Exchange Iwanowska's Fellowship PPN/IWA/2018/1/00006/U/00001/01, the APDA and the Haworth Family Professorship in Neurodegenerative Diseases fund. OR is supported by the National Institutes of Health (NIH; R01 NS078086; U54 NS100693; U54 NS110435), the US Department of Defense (W81XWH-17-1-0249), The Little Family Foundation, Mayo Clinic Functional Genomics of LBD Program, the Mayo Clinic Center for Individualized Medicine, and the Michael J. Fox Foundation for Parkinson's Research (MJFF). FF was the recipient of fellowships from the Younkin Scholar Program and the APDA and was supported in part by the MJFF (15625) and a Gerstner Family Career Development Award from the Mayo Clinic Center for Individualized Medicine (CIM). WS was partially supported by the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) (RF1 NS085070, R01 NS110085, and U54 NS110435), National Institute on Aging (NIA) (R56 AG062556), the Department of Defense Congressionally Directed Medical Research Programs (CDMRP) (W81XWH-17-1-0248), the Florida Department of Health - Ed and Ethel Moore Alzheimer's Disease Research Program (9AZ10) the MJFF (15007), Mayo Clinic Foundation and the Center for Biomedical Discovery (CBD). ZW is partially supported by the Mayo Clinic Center for Regenerative Medicine, gifts from The Sol Goldman Charitable Trust and the Donald G. and Jodi P. Heeringa Family, the Haworth Family Professorship in Neurodegenerative Diseases fund, and The Albertson Parkinson's Research Foundation. He serves as PI or Co-PI on grants from Biogen, Inc. (228PD201), and Biohaven Pharmaceuticals, Inc. (BHV4157-206 and BHV3241-301), and Neuraly, Inc. (NLY01-PD-1). He serves as Co-PI of the Mayo Clinic APDA Center for Advanced Research.
Publisher Copyright:
© Copyright © 2021 Milanowski, Oshinaike, Broadway, Lindemann, Soto-Beasley, Walton, Hanna Al-Shaikh, Strongosky, Fiesel, Ross, Springer, Ogun and Wszolek.
PY - 2021/1/14
Y1 - 2021/1/14
N2 - Introduction: Nigeria is one of the most populated countries in the world; however, there is a scarcity of studies in patients with age-related neurodegenerative diseases, such as Parkinson disease (PD). The aim of this study was to screen patients with PD including a small cohort of early-onset PD (EOPD) cases from Nigeria for PRKN, PINK1, DJ1, SNCA multiplication, and LRRK2 p.G2019S. Methods: We assembled a cohort of 109 Nigerian patients with PD from the four main Nigerian tribes: Yoruba, Igbo, Edo, and Hausa. Fifteen cases [14 from the Yoruba tribe (93.3%)] had EOPD (defined as age-at-onset <50 years). All patients with EOPD were sequenced for the coding regions of PRKN, PINK1, and DJ1. Exon dosage analysis was performed with a multiplex ligation-dependent probe amplification assay, which also included a SNCA probe and LRRK2 p.G2019S. We screened for LRRK2 p.G2019S in the entire PD cohort using a genotyping assay. The PINK1 p.R501Q functional analysis was conducted. Results: In 15 patients with EOPD, 22 variants were observed [PRKN, 9 (40.9%); PINK1, 10 (45.5%); and DJ1, 3 (13.6%)]. Three (13.6%) rare, nonsynonymous variants were identified, but no homozygous or compound heterozygous carriers were found. No exonic rearrangements were present in the three genes, and no carriers of SNCA genomic multiplications or LRRK2 p.G2019S were identified. The PINK1 p.R501Q functional analysis revealed pathogenic loss of function. Conclusion: More studies on age-related neurodegenerative diseases are needed in sub-Saharan African countries, including Nigeria. Population-specific variation may provide insight into the genes involved in PD in the local population but may also contribute to larger studiesperformed in White and Asian populations.
AB - Introduction: Nigeria is one of the most populated countries in the world; however, there is a scarcity of studies in patients with age-related neurodegenerative diseases, such as Parkinson disease (PD). The aim of this study was to screen patients with PD including a small cohort of early-onset PD (EOPD) cases from Nigeria for PRKN, PINK1, DJ1, SNCA multiplication, and LRRK2 p.G2019S. Methods: We assembled a cohort of 109 Nigerian patients with PD from the four main Nigerian tribes: Yoruba, Igbo, Edo, and Hausa. Fifteen cases [14 from the Yoruba tribe (93.3%)] had EOPD (defined as age-at-onset <50 years). All patients with EOPD were sequenced for the coding regions of PRKN, PINK1, and DJ1. Exon dosage analysis was performed with a multiplex ligation-dependent probe amplification assay, which also included a SNCA probe and LRRK2 p.G2019S. We screened for LRRK2 p.G2019S in the entire PD cohort using a genotyping assay. The PINK1 p.R501Q functional analysis was conducted. Results: In 15 patients with EOPD, 22 variants were observed [PRKN, 9 (40.9%); PINK1, 10 (45.5%); and DJ1, 3 (13.6%)]. Three (13.6%) rare, nonsynonymous variants were identified, but no homozygous or compound heterozygous carriers were found. No exonic rearrangements were present in the three genes, and no carriers of SNCA genomic multiplications or LRRK2 p.G2019S were identified. The PINK1 p.R501Q functional analysis revealed pathogenic loss of function. Conclusion: More studies on age-related neurodegenerative diseases are needed in sub-Saharan African countries, including Nigeria. Population-specific variation may provide insight into the genes involved in PD in the local population but may also contribute to larger studiesperformed in White and Asian populations.
KW - DJ1
KW - LRRK2
KW - MLPA
KW - Nigerian population
KW - PINK1
KW - PRKN
KW - Parkinson disease
KW - Sanger sequencing
UR - http://www.scopus.com/inward/record.url?scp=85102149790&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102149790&partnerID=8YFLogxK
U2 - 10.3389/fneur.2020.594927
DO - 10.3389/fneur.2020.594927
M3 - Article
AN - SCOPUS:85102149790
SN - 1664-2295
VL - 11
JO - Frontiers in Neurology
JF - Frontiers in Neurology
M1 - 594927
ER -